GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Jubilant Pharmova Ltd (NSE:JUBLPHARMA) » Definitions » EV-to-EBITDA

Jubilant Pharmova (NSE:JUBLPHARMA) EV-to-EBITDA : 16.79 (As of Jun. 23, 2024)


View and export this data going back to 2003. Start your Free Trial

What is Jubilant Pharmova EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Jubilant Pharmova's enterprise value is ₹138,500 Mil. Jubilant Pharmova's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was ₹8,247 Mil. Therefore, Jubilant Pharmova's EV-to-EBITDA for today is 16.79.

The historical rank and industry rank for Jubilant Pharmova's EV-to-EBITDA or its related term are showing as below:

NSE:JUBLPHARMA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -37.12   Med: 6.68   Max: 17.48
Current: 16.79

During the past 13 years, the highest EV-to-EBITDA of Jubilant Pharmova was 17.48. The lowest was -37.12. And the median was 6.68.

NSE:JUBLPHARMA's EV-to-EBITDA is ranked worse than
59.32% of 708 companies
in the Drug Manufacturers industry
Industry Median: 14.185 vs NSE:JUBLPHARMA: 16.79

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-23), Jubilant Pharmova's stock price is ₹720.05. Jubilant Pharmova's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ₹4.850. Therefore, Jubilant Pharmova's PE Ratio for today is 148.46.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Jubilant Pharmova EV-to-EBITDA Historical Data

The historical data trend for Jubilant Pharmova's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jubilant Pharmova EV-to-EBITDA Chart

Jubilant Pharmova Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.82 8.67 7.29 9.19 13.88

Jubilant Pharmova Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.19 8.50 11.36 9.15 13.88

Competitive Comparison of Jubilant Pharmova's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Jubilant Pharmova's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jubilant Pharmova's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Jubilant Pharmova's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Jubilant Pharmova's EV-to-EBITDA falls into.



Jubilant Pharmova EV-to-EBITDA Calculation

Jubilant Pharmova's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=138499.685/8247
=16.79

Jubilant Pharmova's current Enterprise Value is ₹138,500 Mil.
Jubilant Pharmova's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹8,247 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jubilant Pharmova  (NSE:JUBLPHARMA) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Jubilant Pharmova's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=720.05/4.850
=148.46

Jubilant Pharmova's share price for today is ₹720.05.
Jubilant Pharmova's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹4.850.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Jubilant Pharmova EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Jubilant Pharmova's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Jubilant Pharmova (NSE:JUBLPHARMA) Business Description

Traded in Other Exchanges
Address
1A, Sector 16A, Noida, UP, IND, 201 301
Jubilant Pharmova Ltd is an integrated global pharmaceutical company. The company's segment includes Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research, Development and Manufacturing Organisation and Proprietary Novel Drugs. It generates maximum revenue from the Radiopharma segment. Geographically, it derives a majority of its revenue from Americas and Europe.

Jubilant Pharmova (NSE:JUBLPHARMA) Headlines

No Headlines